^
Association details:
Biomarker:No biomarker
Cancer:Nasopharyngeal Carcinoma
Regimen:DP (cisplatin + docetaxel)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
06/09/2020
Excerpt:
Nasopharyngeal cancer: Recurrent/Unresectable or Metastatic (with no surgery or RT option)…Other Recommended Regimens (First-Line)…Combination Therapy…Cisplatin or carboplatin/docetaxel...or paclitaxel